Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;84(2):248-288.
doi: 10.1016/j.jinf.2021.09.013. Epub 2021 Sep 21.

Antibody titers and protection against a SARS-CoV-2 infection

Chloé Dimeglio  1 , Fabrice Herin  2 , Guillaume Martin-Blondel  3 , Marcel Miedougé  4 , Jacques Izopet  5
Affiliations

Antibody titers and protection against a SARS-CoV-2 infection

Chloé Dimeglio et al. J Infect. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare no conflict of interest

Figures

Fig. 1
Fig. 1.
Study flowchart. The NAb titers were obtained at each time of ELISA screening (July 2020, January 2021) for all ELISA-positive samples. The January 2021 NAb titers for vaccinated HCWs were obtained three weeks after administration of the first or second vaccine dose. Finally, the NAb titers reported for December 2020 and April 2021 were those obtained at the previous screening (July 2020 and January 2021, respectively) and for which an infection occurred during the following three months.
Fig. 2
Fig. 2.
Protection against SARS-CoV-2 according to neutralizing (A) or binding (B) antibody classes.
See this image and copyright information in PMC

Comment in

References

    1. Doria-Rose N., Suthar M.S., Makowski M., O'Connell S., McDermott A.B., Flach B., et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. N Engl J Med. 2021;384(23):2259–2261. doi: 10.1056/NEJMc2103916. - DOI - PMC - PubMed
    1. McMahan K., Yu J., Mercado N.B., Loos C., Tostanoski L.H., Chandrashekar A., et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630–634. doi: 10.1038/s41586-020-03041-6. - DOI - PMC - PubMed
    1. Douxfils J., Gillot C., Mullier F., Favresse J. Post-SARS-CoV-2 vaccination specific antibody decrease - thresholds for determining seroprevalence and seroneutralization differ. J Infect. 2021;S0163-4453(21):00405–00409. doi: 10.1016/j.jinf.2021.08.023. [published online ahead of print] - DOI - PMC - PubMed
    1. Dimeglio C., Herin F., Miedougé M., Cambus J.P., Abravanel F., Mansuy J.M., et al. Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France. J Infect. 2020;82(1):e29–e32. doi: 10.1016/j.jinf.2020.09.035. - DOI - PMC - PubMed
    1. Trémeaux P., Lhomme S., Abravanel F., Raymond S, Mengelle C., Mansuy J.M., et al. Evaluation of the Aptima™ transcription-mediated amplification assay (HologicⓇ) for detecting SARS-CoV-2 in clinical specimens. J Clin Virol. 2020;129 doi: 10.1016/j.jcv.2020.104541. - DOI - PMC - PubMed

Substances